Hematologia

Editorial | Impacto das células tumorais circulantes como componentes do estadiamento do mieloma múltiplo.

5 Jul, 2022 | 11:19h

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? – Journal of Clinical Oncology

Estudos originais:

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma – Journal of Clinical Oncology

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma – Journal of Clinical Oncology

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology

---

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

---

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter (fio – clique para saber mais)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials🧵

— The Lancet Haematology (@TheLancetHaem) June 30, 2022

 

---

Estudo randomizado | Lisocabtagene maraleucel vs. cuidado padrão com quimioterapia de resgate seguida de transplante autólogo de células-tronco como segunda linha de tratamento em pacientes com linfoma B de células grandes recidivante ou refratário.

22 Jun, 2022 | 21:22h

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

---

Estudo de braço único fase 2 | Antivirais de ação direta como tratamento primário de linfomas não Hodgkin indolentes associados ao vírus da hepatite C.

21 Jun, 2022 | 12:32h

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

---

Desfechos de 10 anos de estudo randomizado | Momento da cura para crianças e jovens adultos com leucemia linfoblástica aguda (LLA) independe de fatores de risco iniciais.

21 Jun, 2022 | 12:31h

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

---

Análise de eventos tromboembólicos e trombocitopênicos após vacinação contra COVID-19 com vacinas da AstraZeneca, da Pfizer e da Moderna em 3 países nórdicos.

19 Jun, 2022 | 15:40h

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

---

Diretriz de recomendação | Diagnóstico e tratamento da mastocitose sistêmica.

19 Jun, 2022 | 14:16h

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel – Hematology, Transfusion and Cell Therapy

---

Estudo de coorte | Mortalidade entre pacientes submetidos a transfusão de sangue em relação ao sexo e à paridade do doador.

19 Jun, 2022 | 14:10h

Mortality Among Patients Undergoing Blood Transfusion in Relation to Donor Sex and Parity: A Natural Experiment – JAMA Internal Medicine

Comunicado de imprensa: Red blood cell units from female blood donors do not increase risk of death of transfused patients – Karolinska Institutet

---

Sistema de escore para prognóstico molecular nas síndromes mielodisplásicas.

19 Jun, 2022 | 13:56h

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence

---